HIV protease inhibitors
    8.
    发明授权
    HIV protease inhibitors 有权
    HIV蛋白酶抑制剂

    公开(公告)号:US09079834B2

    公开(公告)日:2015-07-14

    申请号:US13882267

    申请日:2011-10-27

    摘要: Compounds of Formula I are disclosed wherein R1, R2, R3A, R3B, R4A, R4B, R5A, R5B, R6A, R6B, R7, R8 and R9 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

    摘要翻译: 公开了式I的化合物,其中R1,R2,R3A,R3B,R4A,R4B,R5A,R5B,R6A,R6B,R7,R8和R9如本文所定义。 式I所包括的化合物包括可以在体内代谢为HIV蛋白酶抑制剂的HIV蛋白酶抑制剂和其它化合物的化合物。 化合物及其药学上可接受的盐可用于预防或治疗HIV感染以及预防,治疗或延迟艾滋病的发病。 化合物及其盐可以用作药物组合物中的成分,任选与其它抗病毒剂,免疫调节剂,抗生素或疫苗组合使用。

    Cathespin cysteine protease inhibitors
    10.
    发明授权
    Cathespin cysteine protease inhibitors 有权
    夹心半胱氨酸蛋白酶抑制剂

    公开(公告)号:US07312353B2

    公开(公告)日:2007-12-25

    申请号:US10568495

    申请日:2004-08-19

    IPC分类号: C07C255/22 C07C229/24

    摘要: This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

    摘要翻译: 本发明涉及由下式表示的新一类化合物,其中G,E,E,n,R 1,R 2,R 2, 其中指出其中的半胱氨酸蛋白酶抑制剂,包括但不限于组织蛋白酶K,L,S和B的抑制剂。这些化合物可用于治疗 指出了骨吸收抑制的疾病,例如骨质疏松症。